Cite
430PEmetic risk of carboplatin plus pemetrexed is higher than that of carboplatin plus paclitaxel in patients with lung cancer: A propensity score-matched analysis.
MLA
Matsuo, K., et al. “430PEmetic Risk of Carboplatin plus Pemetrexed Is Higher than That of Carboplatin plus Paclitaxel in Patients with Lung Cancer: A Propensity Score-Matched Analysis.” Annals of Oncology, vol. 30, Nov. 2019, p. N.PAG. EBSCOhost, https://doi.org/10.1093/annonc/mdz434.011.
APA
Matsuo, K., Shimokawa, M., Hayashi, T., Iihara, H., Nakano, T., Imakyure, O., & Egawa, T. (2019). 430PEmetic risk of carboplatin plus pemetrexed is higher than that of carboplatin plus paclitaxel in patients with lung cancer: A propensity score-matched analysis. Annals of Oncology, 30, N.PAG. https://doi.org/10.1093/annonc/mdz434.011
Chicago
Matsuo, K, M Shimokawa, T Hayashi, H Iihara, T Nakano, O Imakyure, and T Egawa. 2019. “430PEmetic Risk of Carboplatin plus Pemetrexed Is Higher than That of Carboplatin plus Paclitaxel in Patients with Lung Cancer: A Propensity Score-Matched Analysis.” Annals of Oncology 30 (November): N.PAG. doi:10.1093/annonc/mdz434.011.